Long‐Term Treatment With Systemic Rifampicin and Clindamycin for Epidermal Growth Factor Receptor Inhibitor‐Related Acneiform and Mucocutaneous Rash: A Valid Therapeutic Option

Documenti analoghi

• Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash
  di: Giovanni Paolino, et al.
  Pubblicazione: (2025)
• Lebrikizumab After Multiple Prior Advanced Therapies in Moderate‐To‐Severe Atopic Dermatitis: A Real‐World Case Series
  di: Giovanni Paolino, et al.
  Pubblicazione: (2026)
• Zanubrutinib‐Induced Acneiform Rash in a Patient With Waldenstrom’s Macroglobulinemia
  di: Silvia Robuffo, et al.
  Pubblicazione: (2026)
• Immune cutaneous reactions in orf and in pseudocowpox viruses: clinicopathologic correlations and management to avoid misdiagnosis
  di: Giovanni Paolino, et al.
  Pubblicazione: (2024)
• Analysis of trichoscopic images using deep neural networks for the diagnosis and activity assessment of alopecia areata – a retrospective study
  di: Raffaele Dante Caposiena Caro, et al.
  Pubblicazione: (2025)